news
SARS-CoV-2 triggers antibodies from previous coronavirus infections
A new study has shown that previous coronavirus infection may contribute to the immune response of patients infected with SARS-CoV-2.
List view / Grid view
Antibodies
webinar
High content screening reveals the phenotypic landscape of intestinal organoid regeneration
21 January 2021 | By Yokogawa Life Innovations
Watch our on-demand webinar and learn how image-based phenotypic screening relies on extraction of multivariate information from cells cultured in a large number of screened conditions. In this webinar, we explore the application of complex and biologically relevant model systems for drug screening, such as small intestinal organoids.
news
Novel nanobody combinations protect cells from SARS-CoV-2 in vitro
By combining nanobodies targeting different regions of the SARS-CoV-2 Spike protein, researchers were able to protect cells from infection.
news
Study shows how to improve cancer treatment with anti-OX40 antibodies
New insights into the mechanisms of anti-OX40 antibodies could enable their therapeutic activity to be manipulated to treat different tumours.
video
Webinar: Novel flow cytometry ACE-2 blocking assay
This webinar from Bio-Techne demonstrates how to use a novel in vitro flow cytometry-based assay to monitor SARS-CoV-2 binding to ACE-2.
news
2B7 antibody could be the breakthrough needed for dengue fever therapies
Scientists show that an antibody targeting a protein acting as a viral toxin, can prevent the dengue virus from infecting human cells.
video
Webinar: Targeting oxygen sensing in cancer
This webinar from Bio-Techne discusses canonical and alternative oxygen sensing mechanisms implicated in cancer therapy resistance and recurrence.
news
Analysis finds COVID-19 infection may provide protective immunity
A new analysis suggests SARS-CoV-2-specific antibodies remain relatively stable for eight months and Spike protein-specific memory B cells increase in number over time.
whitepaper
Whitepaper: Virus vaccine research – accelerated workflows
Discover how workflows are being accelerated to speed up the vaccine research and development process while maintaining safety and immunogenicity.
news
Activating STING enhances CAR T-cell activity in solid tumours, shows study
Researchers were able to eradicate breast cancer in mice when they combined CAR T cells with STING pathway agonists and immunotherapeutic antibodies.
news
Assay reveals potency of neutralising antibodies in COVID-19 patients
Researchers have shown that neutralising antibodies developed in COVID-19 patients were less potent if from those with severe or fatal disease.
news
Inhaled vaccine induces strong immune response in animal models
Scientists report their phage-based inhaled vaccine delivery system elicited a robust antibody response in both mice and non-human primates.
news
Triggering an IgA response could increase COVID-19 vaccine efficacy
Two new studies suggest that SARS-CoV-2-specific IgA antibodies are more neutralising and therefore COVID-19 vaccines should encourage an IgA response.
news
Synthetic llama antibodies used to rescue mutated proteins
Engineered deubiquitinases combines a synthetic nanobody that recognises a protein that can rescue proteins tagged for destruction.
news
Microscopy reveals four classes of SARS-CoV-2 neutralising antibodies
Researchers show that neutralising antibodies targeting the SARS-CoV-2 Spike protein have four distinct structures.
